Reimbursement

The Art of Medical Device Reimbursement: Interview with Randel Richner, Founder of Neocure Group

510(k) this.  PMA that.  What does it matter if a device is FDA approved, but not reimbursable?

Could reimbursement possibly be more important than the regulatory environment within the medical device space?  

Randel Richner is here to help us better understand the reimbursement game. Listen up!

Who is Randel Richner?

Randel Richner is the founder of Neocure Group, a consulting firm with offices located in Boston, Washington D.C. and California. She founded Neocure in 2006 as a consulting firm specializing in health policy, reimbursement strategy, health economics, and global planning to support biopharmaceutical and medical technology companies. She served as Vice President, Global Government Affairs for Boston Scientific Corporation (BSC) from 1997 until June, 2006. At Boston Scientific, Richner built a global reimbursement and outcomes strategic process for new and existing less invasive medical technologies for BSC product platforms. Over the nine-year period, she was actively engaged in national and international policy and legislative arenas as an advocate for the benefits of innovative medical technology, FDA, regulatory, international trade and payment issues.

Richner holds a Master’s Degree in Public Health Policy and Administration and a Bachelor of Science in Nursing, magna cum laude, from the University of Michigan. Before her career in health economics and policy, she was a practicing dialysis and transplant nurse for 13 years at the University of Michigan Hospital and Northern Michigan Hospital.

Interview Highlights with Randel Richner

  • A recent case study of how Randel helped save a medical device company from severe reimbursement implications within a week’s time.
  • How Randel’s team at Neocure helps medtech and biopharma companies get paid through effective reimbursement and health economic strategies.
  • Randel’s dynamic background and how she came to found the Neocure Group.
  • Neocure’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.
  • The massive implications for medtech companies based on the healthcare reform wildcard.
  • How Neocure’s unique data trends help their medtech and biotech customers achieve effective healthcare economic outcomes.
  • The importance of defining the difference between how hospitals get paid and how physicians get paid.
  • Why it’s necessary for medtech and biotech companies to catch up to the investors in terms of understanding the importance of reimbursement.
  • What Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.

Listen to the Interview with Randel Richner

Read the Interview with Randel Richner

Download a copy of the interview transcript right here.

You May Like These Articles

  • Recent
  • Featured
  • Related

The Importance of Understanding Clinical Trial Design as a Medtech CEO: Interview with Nadim Yared, CEO of CVRx

In this interview with Nadim Yared, CEO of CVRx, we discuss his journey with the company, including Nadim’s expertise on clinical trial strategy, startup funding, and working with FDA & CMS.

3 Critical Goals Every New Medical Device Should Aim For: Interview with Doug Evans, CEO of Lungpacer Medical

In this interview with Doug Evans, CEO of Lungpacer Medical, we discuss tips for launching medtech startups, working with payers & regulators, commercializing novel technologies, and we'll learn more about Lungpacer's impressive system.

Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health

In this interview with Renee Ryan, CEO of Cala Health, we discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She also shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement.

The Biggest Mistakes to Avoid When Designing Medical Device Prototypes: Interview with Mike Wallace, CEO of DeVoro Medical

In this interview with Mike Wallace, CEO of DeVoro Medical, he tells about the mistakes medtech entrepreneurs often make in the early stages of their companies and how you can pivot when an idea doesn’t pan out.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK

In this interview with Michael Branagan-Harris, he discusses the ideal process medical device companies should follow when launching their products in the UK.

Demystifying Value-Based Healthcare: A Physician Expert Explains All (with Real-World Examples)

In this interview with healthcare thought leader, Dr. Dan Mazanec, he explains how the original concept of bundled payment models started, the shifting financial risk in healthcare, and why care coordination will be so important in the future.

How Will These 2 Major Healthcare Changes Affect Medical Device Companies: Interview with Brian Contos

In this interview with experienced healthcare expert, Brian Contos, he explains the one major initiative that medical device companies need to really grasp in light of healthcare reform.

The Art of Medical Device Reimbursement: Interview with Randel Richner, Founder of Neocure Group

In this interview with Randel Richner, we learn why insurance coverage and reimbursement for your medical device may be more important than regulatory approval.

Success! Your membership is now active.